Friday 5-16-2014 Celgene Corp (CELG) $CELG opened at 148.96

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
Friday 5-16-2014 Celgene Corp (CELG) $CELG opened at 148.96 hitting the high price of 150.20 and a day low of 145.30 with a total volume of 2,863,100. CELG had a previous close of 148.85 and has been seeing an average volume of 2,926,910.

Overall Average: 16% Sell

Recent stock forum discussions about CELG http://investorshangout.com/search?q=CELG&...mp;yt0=Go!

Final Glance: Biotechnology companies
AP - Fri May 16, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)

After Yesterday's Decline of 1.03%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Fri May 16, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.30 to a high of $150.20. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $148.00 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)

Watch for Celgene to Potentially Rebound After Falling 1.03% Yesterday
Comtex SmarTrend(R) - Fri May 16, 3:51PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.30 to a high of $150.20. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $148.00 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)

Midday Glance: Biotechnology companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)

Early Glance: Biotechnology companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)

Upcoming Conferences, Stock Price Movements and Support to Humanitarian Programs - Analyst Notes on Celgene, Biogen Idec, Incyte, Jazz Pharmaceuticals and Medivation
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Incyte Corporation (NASDAQ: INCY), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Medivation Inc. (NASDAQ: MDVN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2548-100free. (full story)

Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2014
Business Wire - Wed May 14, 4:19PM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced more than 65 abstracts reporting on investigational studies in blood and solid tumor cancers will be presented during the 50th American Society of Clinical Oncology meeting in Chicago, Ill. from May 30 to June 3, 2014. (full story)

Critical Alerts For DirecTV, JPMorgan, First Solar, Celgene, and Baidu.com Released By InvestorsObserver
PR Newswire - Wed May 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DTV, JPM, FSLR, CELG, and BIDU. (full story)

Clinical Trial Results, Acquisitions, Healthcare Partnership, and Pricing of Senior Notes - Analyst Notes on Merck, JNJ, Chelsea, Unitedhealth and Celgene
PR Newswire - Tue May 13, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Unitedhealth Group, Inc. (NYSE: UNH) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2377-100free. (full story)

Celgene Rises 2.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 12, 4:00PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.70 to a high of $151.00. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $147.99 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)

After Yesterday's Rally of 2.63% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.70 to a high of $151.00. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $147.99 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)

Will Patterson (PDCO) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 12:00PM CDT
Patterson's (PDCO) bottom-line growth was on par with the Zacks Consensus Estimate. (full story)

Celgene Earnings Review: 18 Days after Announcement Shares Up 3.8% (CELG)
Comtex SmarTrend(R) - Mon May 12, 11:09AM CDT
When Celgene (NASDAQ:CELG) reported earnings 18 days ago on April 24th, 2014, analysts, on average, expected the company to report earnings of $1.65 on sales of $1.8 billion. The company actually reported EPS of $1.67 on sales of $1.7 billion, beating EPS estimates by $0.02 and missing revenue estimates by $35.1 million. Shares of Celgene have climbed from $141.25 to $146.67, representing a gain of 3.8% since the company reported earnings 18 days ago. (full story)

Here's What These $3 Billion Money Managers Have Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Mon May 12, 10:05AM CDT
Every quarter, many money managers have to disclose what they've bought and sold via "13F" filings. Their latest moves can shine a bright light on smart stock picks. Today, let's look at Todd Asset Management. Based in Kentucky, the money managers'... (full story)

Celgene Corporation (CELG) Stock Research Links

CELG Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Perrigo's Reinvention Strategy: A Path to Sustainable Success

Updated Category News Views 152

Perrigo Restructures for Future Growth and Performance Perrigo Company plc (NYSE: PRGO), a recognized leader in the consumer self-care products industry, has embarked on an ambitious path of organizational realignment aimed at ensuring sustainable growth and enhanced operational performance. This strategic initiative is expected to bolster agility and innovation within...

Continue Reading
Eli Lilly Prepares for Weight-Loss Drug Launch Amid FDA Review

Updated Category News Views 225

Eli Lilly's Strategic Inventory Build-Up Eli Lilly and Company (NYSE: LLY) has made headlines recently by accumulating an impressive $1.5 billion worth of inventory for its experimental oral weight-loss pill, orforglipron. This move comes in light of the anticipated decision by the FDA, which could take place in the near future. The increase in inventory value represents...

Continue Reading
Roblox's CFO Transition: Leadership Change and Future Prospects

Updated Category News Views 352

Roblox Corporation Announces CFO Transition Roblox Corporation (NYSE:RBLX) has recently made headlines as its Chief Financial Officer, Michael Guthrie, prepares to leave his post to focus on personal pursuits. This change reflects a significant moment in the company's leadership dynamics, with the announcement stemming from a formal Separation and Transition Agreement....

Continue Reading
MaxCyte's 2024 Financial Results Highlight Growth and Innovation

Updated Category News Views 149

MaxCyte Reports Positive Financial Results for 2024 MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a renowned company at the forefront of cell engineering, has shared exciting preliminary financial outcomes for its fourth quarter and the entire year of 2024. These results demonstrate steady growth in revenue and a stronger position in the rapidly evolving cell therapy industry....

Continue Reading
XORTX Therapeutics Invites Shareholders to Participate Actively

Updated Category News Views 113

XORTX Therapeutics Encourages Shareholder Participation CALGARY, Alberta – XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a leading clinical pharmaceutical company focused on developing innovative therapies for progressive kidney disease, is reaching out to its shareholders. They want to remind everyone about the important voting deadline for the...

Continue Reading